An interventional study of Norepinephrine started prophylactically immediately post induction of general anesthesia and Norepinephrine infusion will only initiated if mean arterial pressure <65 mmHg despite preload optimization (stroke volume variation <12%) or if systemic vascular resistance <800 dynes•s/cm⁵ in Noradrenaline, sponsored by Mansoura University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Mansoura University · Not applicable, Interventional, and Prevention
goal-directed fluid therapy has demonstrated benefits on postoperative organ function, vasopressor support with norepinephrine is commonly employed to maintain perfusion pressure, though its renal impact in this setting remains incompletely characterized
The aim of this randomized prospective trial is to evaluate whether post-induction prophylactic norepinephrine infusion reduces the incidence of postoperative acute kidney injury (AKI) in adult recipients undergoing living donor liver transplantation, through attenuation of intraoperative hypotension and preservation of renal perfusion
1,641 studies on the registry are indexed under Acute Kidney Injury; 380 are open to participants now.
This study's planned enrollment of 84 is below the median of 100 across 786 interventional studies indexed under Acute Kidney Injury.
Browse Acute Kidney Injury studies →Mansoura University is the lead sponsor of 1,114 studies on the registry; 185 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
* Norepinephrine infusion will not be initiated post induction. * It will only be started if mean arterial pressure \<65 mmHg despite preload optimization (stroke volume variation \<12%) or if Systemic Vascular Resistance\<800 dynes•s/cm⁵. * Starting dose 0.03 - 0.06 μg/kg/min and titrated up to 0.5 μg/kg/min to restore mean arterial pressure ≥65 mmHg
Drug: Norepinephrine started prophylactically immediately post induction of general anesthesia
* Norepinephrine infusion will not be initiated post induction. * It will only be started if mean arterial pressure \<65 mmHg despite preload optimization (stroke volume variation \<12%) or if Systemic Vascular Resistance\<800 dynes•s/cm⁵. * Starting dose 0.03 - 0.06 μg/kg/min and titrated up to 0.5 μg/kg/min to restore mean arterial pressure ≥65 mmHg. * Infusion will be stopped if mean arterial pressure ≥ 65 mmHg and Systemic Vascular Resistancewithin normal range 800-1200 dynes•s/cm⁵
Drug: Norepinephrine infusion will only initiated if mean arterial pressure <65 mmHg despite preload optimization (stroke volume variation <12%) or if systemic vascular resistance <800 dynes•s/cm⁵
Norepinephrine infusion will be started prophylactically immediately post induction at a dose of 0.03 - 0.06 μg/kg/minute as long as mean arterial pressure \< 90 mmHg or systemic vascular resistance\< 1200 dynes•s/cm⁵
* Norepinephrine infusion will not be initiated post induction. * It will only be started if mean arterial pressure \<65 mmHg despite preload optimization (stroke volume variation \<12%) or if stroke volume variation \<800 dynes•s/cm⁵. * Starting dose 0.03 - 0.06 μg/kg/min and titrated up to 0.5 μg/kg/min to restore mean arterial pressure ≥65 mmHg
Incidence of postoperative acute kidney injury defined according to the Kidney Disease Improving Global Outcome (KDIGO) criteria
Incidence
Time frame: within the first 7 days postoperatively
Post-operative renal perfusion Assessed by renal resistive index (RRI) measured by ultrasound (US)
index
Time frame: at 24 then at 72 hours Post-operatively
Incidence of any norepinephrine specific side effects
Incidence
Time frame: within intraoperative period
Total intraoperative fluid volume administered (crystalloids, colloids and blood products)
milliliter
Time frame: intraopeatively
Diuretics use and their doses (Furosemide will be administered when clinically indicated for volume overload or persistent oliguria after adequate intravascular volume status has been established)
mg
Time frame: intraoperatively and 7 days postoperatively
Incidence and duration of intraoperative hypotension (mean arterial pressure less than 65)
Incidence
Time frame: intraoperatively
Serial changes in estimated glomerular filtration rate (eGFR) calculated by the creatinine-based equation at baseline
mL/min/1.73 m²
Time frame: postoperative at day 1, 3, 7, 30, and 90
Fibrinogen/Albumin Ratio calculation
mg/dL
Time frame: at 24 then at 72 hours Post-operatively
Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.
Of 239 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 44. This study's planned 24 months is below that.
Counting every sponsor, half of 255 studies reached it within 26 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.